Proteologics is a biopharmaceutical company exploiting the UBIQUITIN system for the discovery and development of novel therapeutics. Drs. Avram Hershko and Aaron Ciechanover - 2004 Nobel Prize in Chemistry laureates for the discovery of the ubiquitin system - lead our distinguished scientific advisory board.
Proteologics focuses primarily on discovering inhibitors for specific E3 ubiquitin ligases (E3). These enzymes control the conjugation of ubiquitin to target proteins, regulating protein breakdown and a variety of cellular processes. E3s are believed to offer novel drug targets for many types of cancer, metabolic disease, viral infections and CNS related disorders.
In September 2008, Proteologics and Teva Pharmaceutical Industries Ltd (Teva) signed a license agreement under which Teva received a license to further develop and commercialize lead molecules that are generated from three drug discovery programs that are currently still being developed by Proteologics for Teva.
In February 2010, Proteologics signed a collaboration agreement with GlaxoSmithKline LLC (GSK) under which GSK and Proteologics will collaborate on six drug discovery projects.
In March 2010, Proteologics completed an Initial Public Offering on the Tel-Aviv Stock Exchange.